8-K filing — Jaguar Health, Inc. (JAGX)
Filed: 2026-11-03 AccNo: 0001193125-26-445055 Size: 138 KB Item 8.01: Other Events
Filings · News reference
Jaguar Health Files S-3 Registration Statement and Provides Clinical Trial Update
Jaguar Health has filed an SEC Form S-3 to register up to $75 million in securities and announced the completion of enrollment for its pivotal crofelemer trial in microvillus inclusion disease (MVID).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
Jaguar Health Provides Update On Special Stock Dividend; Nasdaq Sets October 16 Ex-Dividend Date
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
Jaguar Health Demonstrates Recap Of Preliminary Data At American College Of Gastroenterology Annual Scientific Meeting For Its Current Trial Of Crofelemer Powder For Oral Solution In Adult Patients With Type 1 Short Bowel Syndrome With Intestinal Failure
Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologies led gainers, while NFT Ltd. led decliners.